178 related articles for article (PubMed ID: 24366299)
21. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases.
Wybranski C; Zeile M; Löwenthal D; Fischbach F; Pech M; Röhl FW; Gademann G; Ricke J; Dudeck O
Radiat Oncol; 2011 Apr; 6(1):43. PubMed ID: 21524305
[TBL] [Abstract][Full Text] [Related]
22. A prospective, multi-centre trial of multi-parametric MRI as a biomarker in anal carcinoma.
Jones M; Hruby G; Coolens C; Driscoll B; Stanwell P; Kumar M; Capp A; Sridharan S; Arm J; Gallagher S; Holder C; Oldmeadow C; Martin J
Radiother Oncol; 2020 Mar; 144():7-12. PubMed ID: 31710944
[TBL] [Abstract][Full Text] [Related]
23. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
[TBL] [Abstract][Full Text] [Related]
24. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
Hugonnet F; Fournier L; Medioni J; Smadja C; Hindié E; Huchet V; Itti E; Cuenod CA; Chatellier G; Oudard S; Faraggi M;
J Nucl Med; 2011 Jul; 52(7):1048-55. PubMed ID: 21680694
[TBL] [Abstract][Full Text] [Related]
25. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
[TBL] [Abstract][Full Text] [Related]
26. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
Haider MA; Vosough A; Khalvati F; Kiss A; Ganeshan B; Bjarnason GA
Cancer Imaging; 2017 Jan; 17(1):4. PubMed ID: 28114978
[TBL] [Abstract][Full Text] [Related]
27. Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
Keizman D; Ish-Shalom M; Sella A; Gottfried M; Maimon N; Peer A; Hammers H; Eisenberger MA; Sinibaldi V; Neiman V; Rosenbaum E; Sarid D; Mermershtain W; Rouvinov K; Berger R; Carducci MA
Clin Genitourin Cancer; 2016 Oct; 14(5):420-425. PubMed ID: 27211307
[TBL] [Abstract][Full Text] [Related]
28. Diffusion-weighted imaging: Apparent diffusion coefficient histogram analysis for detecting pathologic complete response to chemoradiotherapy in locally advanced rectal cancer.
Choi MH; Oh SN; Rha SE; Choi JI; Lee SH; Jang HS; Kim JG; Grimm R; Son Y
J Magn Reson Imaging; 2016 Jul; 44(1):212-20. PubMed ID: 26666560
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
30. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Castellano D; Maroto JP; Espinosa E; Grande E; Bolós MV; Llinares J; Esteban E; González Del Alba A; Climent MA; Arranz JA; Méndez MJ; Fernández Parra E; Antón-Aparicio L; Bayona C; Gallegos I; Gallardo E; Samaniego L; García Donas J
Expert Opin Drug Saf; 2018 Jun; 17(6):573-579. PubMed ID: 28535693
[TBL] [Abstract][Full Text] [Related]
31. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
32. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Utility of Histogram Apparent Diffusion Coefficient and R2* for Differentiation of Low-Grade From High-Grade Clear Cell Renal Cell Carcinoma.
Zhang YD; Wu CJ; Wang Q; Zhang J; Wang XN; Liu XS; Shi HB
AJR Am J Roentgenol; 2015 Aug; 205(2):W193-201. PubMed ID: 26204307
[TBL] [Abstract][Full Text] [Related]
35. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease.
Farhadi F; Nikpanah M; Paschall AK; Shafiei A; Tadayoni A; Ball MW; Linehan WM; Jones EC; Malayeri AA
Radiology; 2020 Jun; 295(3):583-590. PubMed ID: 32255415
[TBL] [Abstract][Full Text] [Related]
36. Non-small cell lung cancer: Whole-lesion histogram analysis of the apparent diffusion coefficient for assessment of tumor grade, lymphovascular invasion and pleural invasion.
Tsuchiya N; Doai M; Usuda K; Uramoto H; Tonami H
PLoS One; 2017; 12(2):e0172433. PubMed ID: 28207858
[TBL] [Abstract][Full Text] [Related]
37. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
38. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
39. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
40. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
